Published: 2016-12-19

A retrospective evaluation of acne patients treated with isotretinoin

Fusun Eser Aksu


Background: Although systemic isotretinoin offers more effective alternatives for treatment, as the drug has several side-effects, physicians are hesitatant to recommend the drug. The aim of this research was to retrospectively evaluate the effectiveness, side-effects and validity of systemic isotretinoin treatment on patients with acne, to thereby present experimental data relevant to future usage by patients suffering from acne.

Methods: Patients diagnosed with acne in the Dermatology Polyclinic of the Medical Faculty of KSU between January 2004 and September 2008 was identified from the polyclinic records. Patient data were retrieved from the archives and recorded in the pre-prepared format. A retrospective evaluation was made of the safety and effectiveness of isotretinoin treatment, and the clinical and laboratory test side-effects.

Results: A total of 241 patients were prescribed systemic isotretinoin treatment and started treatment. Of these, 129 of these patients attended regular follow-up examinations and completed the treatment. Systemic isotretinoin was determined to be effective on acne during a treatment period of 23.47±4.5 weeks with a total average dose of 113.73±22.4 mg. There were no serious laboratory test or clinical effects of an intolerable level tolerated which would lead to termination of the treatment.

Conclusions: Systemic isotretinoin treatment is effective and safe for acne vulgaris patients with nodulocystic and papulopustular types of lesion. However, it is essential that the laboratory parameters of hepatic function tests and the lipid profile are checked regularly.


Acne, Dermatology, Isotretinoin

Full Text:



Cunliffe WJ, Simpson NB. Disorders of the sebaceous glands. In: Burns T, Breathnach NC, Cox N, Griffiths C, eds. Rook's Textbook of Dermatology, 7th ed. Blackwell Science, London. 2004;43:15-75.

Al-Khawajah MM. Isotretinoin for acne vulgaris. Int J Dermatol. 1996;35:212-5.

Erdem T, Karakuzu A, Özdemir S, Akdeniz N, Sahan F, Atasoy M. Isotretinoin in nodular and nodulokistic asne treatment, T Klin Dermatol. 1999;9:75-8.

Sarıcaoğlu H, Tunalı S, Alpakut S. The clinical effect of isotretinoin in acne vulgaris treatment. T Klin Dermatol. 1998;8:24-8.

Cunliffe WJ, van de Kerkhof PC, Caputo R, Cavicchini S, Cooper A, Fyrand OL, et al. Roaccutane treatment guidelines: results of an international survey. Dermatology. 1997;194:351-7.

Habif TP. Clinical Dermatology: A Color Guide to Diagnosis and Therapy. 4th ed. Mosby, New York, 2004;162-92.

Haider A, Show JC. Treatment of acne vulgaris. JAMA. 2004;292:726-35.

Layton AM, Knaggs H, Taylor J, Cunliffe WJ. Isotretinoin for acne vulgaris-10 years later: a safe and successful treatment. Br J Dermatol. 1999;129:292-6.

McClane J. Analysis of common side effects of isotretinoin. J Am Acad Dermatol. 2001;45:188-94.

Goulden V, Laytan AM, Cunliffe WJ. Long-term safety of isotretinoin as a treatment of acne vulgaris, Br J Dermatol. 1994;131:360-3.

Ellis CN, Krach KJ. Uses and complications of isotretinoin therapy. J Am Acad Dermatol. 2001;45:150-7.

Leyden JJ. The role of isotretinoin in the treatment of acne: personal observations. J Am Acad Dermatol. 1998;39:45-9.

Türel A, Oztürkcan S, Sahin MT, Türkdogan P. A rare side-effect of systemic isotretinoin treatment: pyogenic granuloma. J Eur Acad Dermatol Venereol. 2003;17:609-11.

DiGiovanna JJ. Isotretinoin effects on bone. J Am Acad Dermatol. 2001;45:176-82.

Chia CY, Lane W, Chibnall J, Allen A, Siegfried E. Isotretinoin therapy and mood changes in adolescents with moderate to severe acne: a cohort study. Arch Dermatol. 2005;141:557-60.

Jick SS, Kremars HM, Scaramozza CV. Isotretinoin use and risk of depression, psychotic symptoms, suicide, and attempted suicide. Arch Dermatol. 2000;136:1231-6.

Cıkım AC, Seyhan M. Effectiveness and side effects of isotretinoin in the treatment of acne vulgaris. Türkderm. 2008;42:51-5.

Zane LT, Leyden WA, Marqueling AL, Manos MM. A population based analysis of laboratory abnormalities during isotretinoin therapy for acne vulgaris. Arch Dermatol. 2006;142:1016-22.

Coşkun BK. Retinoid Tedavisinin Ateroskleroz Gelişimine Etkisi. Fırat Tıp Dergisi. 2004;9:54-8.

Barth JH, Macdonald-Hull SP, Mark J, Jones RG, Cunliffe WJ. Isotretinoin therapy for acne vulgaris: a re-evaluation of the need for measurements of plasma lipids and liver function tests. Br J Dermatol. 1993;129(6):704-7.

McCarter TL, Chen YK. Marked hyperlipidemia and pancreatitis associated with isotretinoin therapy. Am J Gastroenterol. 1992;87:1855-8.

Bershad S, Rubinstein A, Paterniti JR, Le NA, Poliak SC, Heller B, et al. Changes in plasma lipids and lipoproteins during isotretinoin therapy for acne. N Engl J Med. 1985;313(16):981-5.

Lestringant GG, Frossard PM, Agarwal M, Galadari IH. Variations in lipid and lipoprotein levels during isotretinoin treatment for acne vulgaris with special emphasis on HDL-cholesterol. Int J Dermatol. 1997;36:859-62.

Amichai B, Shemer A, Grunwald MH. Low-dose isotretinoin in the treatment of acne vulgaris. J Am Acad Dermatol. 2006;54:644-6.

Ghalamkarpour F, Nasiri S. Isotretinoin in treatment of acne: Its efficacy, side effects, and recurrence rate of disease. Archives of Iranian Medicine. 2006;9:228-30.

Saurat JH. Side effects of systemic retinoids and their clinical management. J am Acad Dermatol. 1992;27:23-8.

Goulden V, Clark SM, Mcgeown C, Cunliffe WJ. Treatment of acne with intermittent isotretinoin, Br J Dermatol. 1997;137:106-8.

Michaëlsson G, Vahlquist A, Mobacken H, Hersle K, Landegren J, Rönnerfält L, et al. Changes in laboratory variables induced by isotretinoin treatment of acne. Acta Derm Venereol. 1986;66(2):144-8.

Schulpis KH, Karikas GA, Georgala S, Michas T, Tsakiris S. Elevated plasma homocysteine levels in patients on isotretinoin therapy for cystic acne. Int J Dermatol. 2001;40:33-6.